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-Cell mass reduction is a central aspect in the development of type 1 and type 2 diabetes, and
substitution or regeneration of the lost -cells is a potentially curative treatment of diabetes.
To study the effects of gastrin on -cell mass in rats with 95% pancreatectomy (95%-Px), a
model of pancreatic regeneration, rats underwent 95% Px or sham Px and were treated with
[15 leu] gastrin-17 (PxG and SG) or vehicle (PxV and SV) for 15 d. In 95% Px rats, gastrin
treatment reduced hyperglycemia (280  52 mg vs. 436  51 mg/dl, P  0.05), and increased
-cell mass (1.15  0.15 mg)) compared with vehicle-treated rats (0.67  0.15 mg, P  0.05).
Gastrin treatment induced -cell regeneration by enhancing -cell neogenesis (increased num-
ber of extraislet -cells in PxG: 0.42  0.05 cells/mm2 vs. PxV: 0.27  0.07 cells/mm2, P  0.05,
and pancreatic and duodenal homeobox 1 expression in ductal cells of PxG: 1.21  0.38% vs.
PxV: 0.23  0.10%, P  0.05) and replication (PxG: 1.65  0.26% vs. SV: 0.64  0.14%; P  0.05).
In addition, reduced -cell apoptosis contributed to the increased -cell mass in gastrin-treated rats
(PxG: 0.07  0.02%, PxV: 0.23  0.05%; P  0.05). Gastrin action on -cell regeneration and survival
increased -cell mass and improved glucose tolerance in 95% Px rats, supporting a potential role of
gastrin in the treatment of diabetes. (Endocrinology 152: 2580–2588, 2011)
-Cell mass reduction is a central aspect in the devel-opment of type 1 and type 2 diabetes (1, 2), and sub-
stitution or regeneration of the lost -cells is a potentially
curative treatment of diabetes. Islet transplantation is an
emerging treatment for diabetes, but the scarcity of human
islets precludes a wide use of islet transplantation unless
alternative sources of -cells are found. Ex vivo generation
of new -cells, either by replication or by differentiation
from stem cells, could provide enough insulin-producing
cells to make this treatment widely available (3). Alterna-
tively, regeneration of the endogenous -cells by replica-
tion of preexisting -cells or by neogenesis from adult
progenitor cells could increase the pancreatic -cell mass
and restore normoglycemia. Thus, the search of molecules
that could induce or stimulate -cell regeneration is the
subject of intensive research.
Gastrin is an enterogastric hormone synthesized by the
G cells located in gastric pits in the antrum of the stomach.
In fetal life, gastrin is expressed in the pancreas, both in
islets and scatteredamongendocrine cells (4).Endogenous
gastrin expression is activated in the developing pancreas
during the secondary transition phase, a period of rapid
pancreatic development when proto-differentiated ducts
proliferate and differentiate into exocrine and endocrine
pancreas (4, 5). In this period, islet precursors in the fetal
duct divide actively and bud from the ductal epithelium to
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form new islets, in a process called islet neogenesis (6). In
the postnatal period, gastrin expression rapidly disap-
pears from the pancreas, and the administration of gastrin
alone has shown no effects on -cell mass in different ex-
perimental conditions (7–10). However, in combination
with epidermal growth factor, gastrin has increased -cell
mass and/or improved glucose homeostasis in several ro-
dent models of diabetes (8, 11), and increased -cell mass
in cultured adult human pancreatic cells (9). In this study
we determined the effect of gastrin administration alone
on islet regeneration in rats that underwent 95% pancre-
atectomy (95%-Px), a well-established model of -cell re-
generation. Gastrin administration increased -cell neo-
genesis and replication, and reduced -cell apoptosis,




Experimental procedures were reviewed and approved by the
Ethical Committee of the University of Barcelona. Male Sprague
Dawley rats (Harlan Interfauna Ibérica, Spain), 4–5 wk of age
and weighing approximately 100 g underwent a 95% Px. Four
groups were studied: 95%-Px rats treated with gastrin (PxG),
95%-Px rats treated with vehicle (PxV), sham-Px rats treated
with gastrin (SG), and sham-Px rats treated with vehicle
(SV). Treatment with [15 leu] gastrin-17 (150 g/kg, Transi-
tion Therapeutics Inc., Toronto, Canada) (12) or vehicle (PBS)
was started immediately before surgery. All animals were in-
jected sc every 12 h for 15 d.
Metabolic control
Fed morning plasma glucose levels were monitored on d 3, d
7, d 10, d 14, and d 15 from the snipped tail with a portable
meter. Blood samples were taken approximately 12 h after the
previous gastrin injection and just before the next injection. Body
weight was simultaneously determined.
Intraperitoneal glucose tolerance test (IPGTT) was per-
formed on d 14 after 95%-Px or sham-Px. Glucose (2 g/kg of
body weight) was injected after 2 h of fasting, and blood glucose
was determined 0, 30, 60, 90, and 120 min after glucose injec-
tion. GraphPad Prism 4 software (GraphPad Software, Inc., San
Diego, CA) was used to calculate the area under the curve.
Px and pancreas remnant harvesting
95%-Px was performed as previously described (13). Briefly,
animals were anesthetized with 5% isofluorane (Forane; Abbott
Laboratories, Madrid, Spain), and maintained anesthetized with
an isofluorane-(1.5%) air mixture. Ninety five percent of the
pancreas was removed carefully by gentle abrasion with cotton
applicators in order to leave major blood vessels intact; the pan-
creatic remnant was the tissue between the common bile duct and
the first loop of the duodenum. Particular attention was placed
to removing the small flap of pancreas attached to the pylorus.
Sham Px was accomplished by breaking splenic and duodenal
mesenteric connections and gently handling the pancreas with
the fingertips. Immediately after surgery, animals received one
dose (2.5 mg/kg) of meloxicam (Metacam; Boehringer Ingel-
heim, Ingelheim, Germany) that was subsequently administered
for the next 3 d after surgery for analgesia. Animals were anes-
thetized 15 d after Px with ketamine (70 mg/kg), diazepam (5.6
mg/kg), and atropine (0.5 mg/kg), and pancreatic remnants were
harvested. In sham animals, the equivalent of the remaining 5%
tissue left after 95%-Px was harvested 15 d after sham surgery.
The excised pancreatic remnants were cleared of fat and lymph
nodes, weighed, fixed in 4% PBS-buffered paraformaldehyde,
and processed for paraffin embedding.
Morphometry
-Cell mass, endocrine non--cell mass, ductal cell mass, and
acinar cell mass was determined by point-counting morphome-
try on immunoperoxidase-stained sections, using a 48-point grid
to obtain the number of intercepts over -cells, endocrine non-
- cells, ductal cells, acinar cells, and over other tissue (14).
Tissue sections were stained for -cells with a rabbit antihuman
insulin antibody (1:50; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), for the endocrine non--cells of the islets with a cock-
tail of antibodies: rabbit antiswine glucagon (1:500, DAKO
Corp., Carpinteria, CA), rabbit antihuman somatostatin (1:500,
DAKO) and rabbit antihuman pancreatic polypeptide (1:2000,
Chemicon International, Inc.,Temecula, CA), and for cytoker-
atins with rabbit anticow PanCK antiserum (1:3000) (DAKO)
and visualized with LSABHRP system (DAKO).
A nomogram relating number of points counted to volume
density and expected relative SE in percentage of mean (10%)
was used to determine the number of intercepts needed for a
representative sampling (15). Approximately 20,000 points
were counted in each pancreas, and at least two to three sections
(150 m apart) were included for each animal. All measurements
were performed by a blinded observer. The relative volume of
each cell type was calculated by dividing the number of points
over that particular cell type by the total number of points over
pancreatic tissue. For each pancreatic cell type of interest, cell
mass was obtained by multiplying its relative volume by the
pancreas weight.
-Cell neogenesis
-cell neogenesis was determined by three indirect meth-
ods (14).
Islets budding from ducts
Islet cells were considered to be budding from ducts when they
were in contact or in near contact (less than five cells apart) with
ductal cells. Insulin-stained sections were visualized, and the
number of islets that were less than five cells apart from ducts
(periductal), and those islets that were more than five cells distant
from ducts (extraductal) were independently counted. Results
were expressed as percentage of periductal or extraductal islets.
Two to three sections (150 m apart) from each pancreas were
analyzed to get a representative result.
Extraislet -cell clusters (groups of less than five cells)
The number of small clusters (less than five cells) of extraislet
insulin-positive cells was counted in insulin-stained pancreatic
sections (14). To standardize counting, the total pancreatic tissue
area was measured with an image-analytical software (AnalySIS
3.0, Soft Imaging System, Münster, Germany), and results were
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expressed as number of extraislet -cell clusters per square mil-
limeter of pancreatic tissue. To get a representative result, three
sections were counted from each pancreatic remnant.
Pancreatic and duodenal homeobox 1 (PDX-1)
expression in ductal cells
Ductal epithelium has been proposed as a source of pancreatic
progenitors (16). We counted the cells in the ductal epithelium
that expressed PDX-1, a major regulator of -cell identity and
function (17) that has been found to be up-regulated in a number
of -cell regeneration models (18–20). Ductal cells were identi-
fied by its typical columnar cell morphology. Slides were treated
with DNase (10 g/ml; Sigma, St. Louis, MO) for 1 h at 37 C.
Immunofluorescence for PDX-1 (1/250; Chemicon Interna-
tional) was performed using as secondary antibody an Alexa
fluor 546-labeled antirabbit IgG (1:400, Molecular Probes, Eu-
gene, OR), and nuclei were stained with DRAQ5 (Biostatus Ltd.,
Leicestershire, UK). Sections were visualized under a confocal
microscope (TCS-SL Spectral Confocal Microscope; Leica, Wet-
zlar, Germany). A minimum of 2500 epithelial ductal cells were
counted per pancreas.
Cell replication
Rats were injected with the thymidine analog 5-bromo-2de-
oxyuridine (BrdU; Sigma), 100 mg/kg ip 6 h before the pancreas
remnant was harvested. To assess -cell replication, sections
were double stained with immunoperoxidase for BrdU using a
Cell Proliferation Kit (Amersham, Amersham, UK), and for in-
sulin using a rabbit antihuman insulin antibody (1:50; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) (14, 21).
Ductal and acinar cell replication was determined by double
immunofluorescence. For BrdU detection the rat anti-BrdU an-
tibody (1:100) (Abcam, Cambridge, UK) combined with the Al-
exafluor 488-labeled antirat IgG (1:400) was used. Rabbit an-
tihuman amylase antibody (1:50; Sigma) and rabbit anticow
cytokeratin antiserum (1:3000; DAKO) were used for acinar and
ductal cell identification, respectively. Alexafluor 555-labeled
antirabbit IgG (1:400) was used as secondary antibody. -Cell,
acinar, and ductal replication was expressed as percentage of
BrdU-positive -cells, acinar cells, or ductal cells respectively.
For -cell replication, at least 1200 cells per pancreas were
counted. For ductal and acinar replication, more than 2500 cells
were counted per pancreas in a minimum of 10 different fields
distributed across the whole pancreatic section.
-Cell apoptosis
Sections were double stained by immunoperoxidase for ap-
optotic nuclei (black) with the terminal deoxynucleotide trans-
ferase-mediated dUTP nick end labeling technique (In Situ Cell
Death Detection Kit, ApopTag; Intergene, Oxford, UK) and for
insulin (brown) using a rabbit antihuman insulin antibody (1:50)
(Santa Cruz Biotechnology) (14). A minimum of 1200 cells were
counted per pancreas.
Individual -cell area
The mean cross-sectional area of individual -cells, a measure
of -cell size, was determined on the immunoperoxidase-stained
sections for insulin with the image-analytical software (AnalySIS
3.0, Soft Imaging System) (21). The perimeter of insulin-positive
area in each islet of the section was carefully traced on the com-
puter’s monitor to exclude any other tissue, and -cell nuclei of
each islet were counted. To calculate the area of the individual
-cells, the total -cell area in the section was divided by the
number of -cell nuclei.
RNA isolation, quantification, and
retrotranscription
RNA was isolated from the pancreas and isolated islets of
PxV (n  10) and SV (n  10) groups; in each group, five
animals were used for gene expression analysis in pancreas, and
five animals were used for gene expression analysis in isolated
islets. Sham-pancreas and pancreatic remnants were rapidly har-
vested, immersed in RNAlater solution (Ambion, Warrington,
UK) and chopped in small pieces (5 mm) and kept overnight at
4 C. RNAlater was then removed and pancreatic tissue was re-
suspended with 1ml TRIzol Reagent (Sigma) for homogeniza-
tion (Ultraturrax; Janke & Kunkel, Stauffen, Germany). Total
RNA was purified according to the manufacturer’s instructions
(PureLink Micro-to Midi System; Invitrogen, Carlsbad, CA). Is-
lets were isolated by collagenase (Collagenase P; Roche, Penz-
berg, Germany) digestion and hand picked to obtain a popula-
tion of pure islets (22). RNA was extracted with Rneasy Mini Kit
(QIAGEN, Crawley, UK), eluted with diethylpyrocarbonate-
treated water and quantified using NanoDrop 1000 Spectro-
photometer (Thermo Scientific, Waltham, MA). RNA quality
was assessed with the Bioanalyzer 2100 (Agilent Technologies,
Inc., Palo Alto, CA). The RNA Integrity Number score ranged
from 6.9 to 8.3 for pancreases and pancreatic remnants and was
higher than 8 for islet samples. cDNA synthesis was performed
from 5 g or 1 g of total RNA for pancreas or isolated islets
respectively using the Superscript III First-strand cDNA synthe-
sis system (Invitrogen).
Quantitative PCR
PCR was run in a 7900HT Fast Real-Time PCR system (Ap-
plied Biosystems) with a 384-well plate allowing all samples to
be amplified in the same run for each gene. Reactions were per-
formed using TaqMan Gene Expression Assays and TaqMan
Gene Expression Master Mix (Applied Biosystems) following
the manufacturer protocol in a final volume of 20 l. In each
reaction 250 ng or 25 ng of pancreas cDNA or isolated islets
cDNA, respectively, were loaded. The assays used in this study
were: cholecystokinin A receptor (cckar): Rn00562164_m1,
cholecystokinin B receptor (cckbr): Rn00565867_m1, and eu-
kariotic 18S rRNA (used as endogenous control). Gene expres-
sion of cckar and cckbr was expressed as Ct, the difference
between cycle threshold (Ct) of each target gene and Ct of the
endogenous control. Ct is the cycle at which sample crosses the
point of detection.
Statistical analysis
Results were expressed as means  SE. Statistics were per-
formed using GraphPad Prism 4 software (GraphPad Software,
San Diego, CA), and differences among means were evaluated
using Student’s t test, the one-way ANOVA combined with
Tukey’s test for post hoc analysis or the two-way ANOVA com-
bined with Bonferroni’s test for post hoc analysis as appropriate.
P  0.05 was considered significant.
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Results
Gastrin treatment improved glucose homeostasis
in 95%-Px rats
All Px rats treated with vehicle developed hyperglyce-
mia that was already detected on d 3 (193  39 mg/dl vs.
SV: 110  2 mg/dl, P  0.05), and that was severe from
d 7 (318  40 mg/dl) until the end of the study (d 15: 436 
51 mg/dl) (Fig. 1A). Gastrin treatment prevented and de-
layed the development of hyperglycemia: 58% (seven of
12) of PxG rats maintained nor-
moglycemia throughout the study, and
the appearance of hyperglycemia was
delayed in the remaining animals (d 3:
169  34 mg/dl; d 7: 265  25 mg/dl,
P  ns vs. SV group). The IPGTT
showed similar blood glucose levels in
normoglycemic PxG (PxG/NG)
and sham-operated animals (area under
the curve of PxG/NG: 19404  1077;
SV: 14607  1048), and lower than in
PxV groups (PxV: 46,892  3450,
P  0.01) (Fig. 1B). Pancreatectomized
rats treated with vehicle and gastrin
showed similar weight gain (Supple-
mental Appendix 1 published on The
Endocrine Society’s Journals Online
web site at http://endo.endojournals.
org), indicating that the improved glu-
cose homeostasis found in PxG rats was not due to an
anorectic action of gastrin.
Gastrin treatment increased -cell mass in Px rats
-Cell mass was higher in the pancreatic remnant of
gastrin-treated rats (PxG: 1.15  0.15 mg) than in
PxV (0.67  0.15 mg, P  0.05) and sham-operated rats
(SV: 0.31  0.07 mg; P  0.001) (Fig. 2A). In PxV rats
-cell mass was doubled compared with SV animals, but
differences did not reach statistical significance (P 
0.083). Gastrin treatment had no effect on SG animals
that showed similar blood glucose, body weight, IPGTT,
and -cell mass (0.27  0.06 mg) than SV group (Supple-
mental Appendix 2). Thus, no additional studies were per-
formed in SG group.
The endocrine non--cell mass (, , and pancreatic
polypeptide cells) was approximately 2 times higher in
PxG group than in PxV rats (Fig. 2B). Ductal and
acinar cell masses were similar in pancreatic remnants
from both Px groups (Fig. 2, C and D).
Gastrin treatment increased -cell neogenesis and
replication and reduced -cell apoptosis
-Cell neogenesis
-Cell neogenesis was determined by three indirect
methods: quantification of ductal cells expressing PDX-1,
of islets budding from ducts, and of extraislet -cells
(groups of 5 cells).
The percentage of ductal cells expressing the transcrip-
tion factor PDX-1 was increased in gastrin-treated rats
(PxG: 1.21  0.38%) compared with PxV (0.23 
0.10%, P  0.03), and with SV rats (0.28  0.21%, P 
0.05) (Fig. 3, A–D). The percentage of periductal islets was
FIG. 1. Effects of gastrin treatment on metabolic evolution of 95%-Px rats. A, Blood glucose
of 95%-Px rats treated with vehicle (PxV; circles, n  9), with gastrin (PxG; triangles, n 
12) and sham-operated rats treated with vehicle (SV; squares, n  10). B, Intraperitoneal
glucose tolerance tests of 95%-Px rats treated with vehicle (PxV; circles , n  8), gastrin-
treated Px rats that remained normoglycemic (PxG/NG; triangles, n  7), and sham-operated
rats (SV; squares, n  9), Values are means  SE. *, P  0.05 vs. all other groups for
ANOVA repeated measures. ANOVA: P  0.05; #, P  0.05 vs. SV for Tukey’s test, †, P 
0.05 vs. all other groups for Tukey’s test.
FIG. 2. Effects of gastrin treatment on -cell mass (A), endocrine non-
-cell mass (B), ductal cell mass (C), and acinar cell mass (D) of
pancreatic remnants of sham-operated rats (SV, n  10), vehicle-
treated 95%-Px rats (PxV, n  9), and gastrin-treated 95%-Px rats
(PxG, n  12).Values are means  SE. ANOVA: P  0.05, *, P  0.05
vs. all other groups; †, P  0.05 vs. SV group for Tukey’s test.
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higher in pancreatectomized rats than in sham-operated
rats (PxV: 87.1  6.5%; SV: 44.7  0.3%; P  0.05).
Gastrin treatment did not further increase the percentage
of periductal islets (PxG 79.4  4.1%) (Fig. 3E). The
number of extraislet -cells was doubled in vehicle-treated
Px rats compared with sham-operated rats (PxV: 0.29 
0.05 cells/mm2, SV: 0.11  0.02 cells/mm2; P  0.05)
and was further increased in gastrin-treated Px rats
(PxG: 0.46  0.04 cells/mm2; P  0.05 vs. both PxV
and SV groups) (Fig. 3F). Overall, these results indicate
that gastrin treatment enhanced -cell neogenesis.
-Cell replication
-Cell replication was doubled in gastrin-treated Px
rats compared with sham-operated rats (PxG: 1.65 
0.26%; SV: 0.64  0.14%; P  0.05) (Fig. 4A). -Cell
replication in PxV rats (1.07  0.15%) was not signif-
icantly different from PxG (P  0.07) or SV (P 
0.083) groups.
Apoptosis
-Cell apoptosis was increased in 95%-Px rats treated
with vehicle compared with sham-operated animals
(PxV: 0.23  0.05%; SV: 0.08  0.02; P  0.05) (Fig.
4B). Gastrin treatment protected -cells from the in-
creased apoptosis found in PxV rats
(PxG: 0.07  0.02%, P  0.05 vs.
PxV).
Cross-sectional individual -cell
size and islet size
The area of individual -cells was sim-
ilarly increased in 95%-Px rats treated
withgastrinorwithvehicle (PxG:244
13m2,PxV:26920m2)compared
with sham-operated rats (SV: 197  16
m2, P  0.05), indicating that gastrin
treatment did not induce further -cell hy-
pertrophy (Fig. 4C).
Gastrin-treatment increased
ductal and acinar cell replication
in pancreatic remnants
Ductal cell proliferation was higher in
95%-Px rats treated with gastrin than in
PxV and SV groups (PxG: 1.49 
0.19%; PxV: 0.89  0.14%; SV:
0.35  0.15%, P  0.05) (Fig. 5C). Aci-
nar cell replication was also increased in
PxG group (1.38  0.28%) compared
with PxV (0.48  0.12%, P  0.05)
and SV (0.46  0.07%, P  0.05)
groups. (Fig. 5F).
Similar effects of gastrin on replication and
apoptosis in
95%-Px normoglycemic and hyperglycemic rats
Because chronic hyperglycemia impairs -cell prolifer-
ation and induces -cell apoptosis (23), we analyzed the
effects of gastrin treatment in the animals that remained nor-
moglycemicandthatdevelopedhyperglycemia.-Cellmass,
neogenesis, replication, and apoptosis were similar in
PxG rats that remained normoglycemic and in those
that developed hyperglycemia after Px (Supplemental
Appendix 3), indicating that the effects of gastrin on
-cells were not due to the improved metabolic control
of gastrin-treated animals, and suggesting a direct effect
of gastrin on -cells.
Expression of gastrin receptors genes cckar and
cckbr in pancreas and islets
The enhanced -cell replication and reduced -cell ap-
optosis found in PxG rats suggested a direct action of
gastrin on pancreatic -cells. However, the expression of
the specific gastrin receptor (cholecystokinin B receptor;
CCKBR) in islets is not well established. Thus, we deter-
mined the expression of cckbr and cckar genes in the pan-
FIG. 3. Effects of gastrin treatment on -cell neogenesis. Confocal images of PDX-1
immunofluorescence in pancreatic remnants of sham-operated rats (SV, n  6) (A), vehicle-
treated 95%-Px rats (PxV, n  6) (B), and gastrin-treated 95%-Px rats (PxG, n  6) (C).
Insets show the nuclear labeling of PDX-1 in epithelial ductal cells. D, Quantification of PDX-1
expression in ductal cells. E, Percentage of islets within the ducts or less than five cells apart
from ducts (dashed bars) and percentage of islets more than five cells apart from ducts
(squared bars). F, Number of -cell clusters with less than five -cells. Values are means  SE.
ANOVA: P  0.05. *, P  0.05 vs. all other groups; , P  0.05 vs. periductal islets of Px
groups; #, P  0.05 vs. extraductal islets of PxV group and †, P  0.05 vs. SV for Tukey’s
test.
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creas and in isolated islets of PxV and SV animals.
cckar gene was similarly expressed in pancreas and iso-
lated islets from PxV and SV groups. In contrast, cckbr
was exclusively expressed in the pancreas of PxV rats
and was detected neither in the pancreas of SV rats nor
in isolated islets of Px or SV rats (Table 1).
Discussion
In this study we have shown that gastrin treatment re-
duced hyperglycemia in 95%-Px rats and increased pan-
creatic -cell mass by enhancing -cell neogenesis and
replication and reducing -cell apoptosis.
Partial Px is an established model of -cell regeneration
that shows very active cell regeneration immediately after
surgery that gradually decreases and by d 14 has returned
to basal levels (24–26). In 95%-Px rats, the regenerative
response is insufficient to overcome the reduction in -cell
mass, and severe hyperglycemia develops soon after Px, as
shown by the metabolic evolution of vehicle-treated rats.
In this study, gastrin treatment reduced the severity of
hyperglycemia in 95%-Px rats, and in more than half of
the animals completely prevented the development of hy-
perglycemia, and even of glucose intolerance, as shown by
the normal glucose levels in the IPGTT. Gastrin has no
known effects on insulin secretion, and the beneficial ef-
fects on glucose control can be attributed to the increased
-cell mass.
Gastrin treatment enhanced -cell neogenesis as indi-
cated by the higher percentage of extraislet -cells and the
increased expression of the -cell transcription factor
PDX-1 in ductal cells of 95%-Px rats treated with gastrin.
A role for gastrin on -cell neogenesis has been suggested
in the fetal pancreas when gastrin and gastrin receptors are
transiently and specifically expressed during the second-
ary transition phase (4, 5, 27, 28). Indirect evidence for a
role of gastrin in islet neogenesis was obtained in patients
with hypergastrinemia caused by gastrin-ex-
pressing islet tumors and atrophic gastritis that
showed nesidioblastosis, an abnormal persis-
tence of active islet neogenesis in the postnatal
pancreas characterized by islets budding from
pancreatic ducts (29). In animal models the
combination of gastrin with an epidermal
growth factor family ligand (8, 10) or a gluca-
gons-like peptide 1 analog induced -cell neo-
genesis (7, 12), and in the INGAS/TGF- dou-
ble transgenic mice an increased number of
-cells was present within the metaplastic
ducts (30). However, in the normal pancreas
gastrin alone showed no effects on -cell neo-
genesis or mass. We have now found that treat-
ment with gastrin alone increased -cell neogenesis and
mass in pancreatectomized rats but had no effect on sham
animals. Overall, the results suggest that gastrin exerts no
neogenic effect on the normal adult rat pancreas, but it
may become an important factor when the tissue un-
dergoes remodeling, an interpretation supported by the
neogenic effect of gastrin in rats with pancreatic duct li-
gation (11).
Pancreatic ducts are considered to harbor adult pro-
genitor cells capable to differentiate into endocrine and
exocrine pancreas after partial Px (26), in a process that
would recapitulate the embryonic development by reac-
tivating latent acinar/islet precursors in pancreatic ducts
(26). The ductal origin of new exocrine and endocrine cell
types has been recently shown in postnatal and adult mice
using the lineage tracing method (16), although other
studies yielded negative results (31). Our finding of an
increased expression of the -cell transcription factor
PDX-1 in ductal cells of gastrin-treated animals, and the
higher percentage of periductal islets in gastrin and vehi-
cle-treated animals after 95% Px, is consistent with the
proposed role of ductal cells in -cell neogenesis. The tran-
sient increment in PDX-1 expression in ductal cells after
partial Px has been also associated with ductal cell pro-
liferation (21). Supporting this association, we found that
PDX-1 expression in ductal cells and ductal cell replica-
tion were both increased in gastrin-treated rats 15 d after
Px, but they were not increased in pancreatectomized an-
imals treated with vehicle.
-Cell proliferation was modestly enhanced by gastrin
treatment in pancreatectomized rats. The mitogenic effect
of gastrin was found both in the animals that remained
normoglycemic and in those that became hyperglycemic
after Px, indicating that the gastrin-increased -cell pro-
liferation was not dependent on blood glucose. However,
in rats with pancreatic duct ligation, the acute adminis-
tration of gastrin had not increased -cell replication (11).
FIG. 4. Effects of gastrin treatment on -cell replication (A), apoptosis (B), and -cell
size (C) in sham-operated rats (SV, n  10), vehicle-treated 95%-Px rats (PxV,
n  9) and gastrin-treated 95%-Px rats (PxG, n  12). Values are means  SE.
ANOVA: P  0.05; #, P  0.05 vs. SV group and *, P  0.05 vs. all other groups
for Tukey’s test.
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Differences between these two experimental models, dose
and duration of gastrin treatment, and day of pancreas
analysis could account for the different results. In patients
with hypergastrinemia caused by gastrin-secreting tumors
the size of islets is increased (29, 32, 33) and, more re-
cently, increased -cell replication, fractional -cell area,
and mean islet size have been identified in islets adjacent
to gastrinomas, suggesting a paracrine effect of gastrin on
-cell replication (34). Partial Px is a well-established
model of -cell regeneration in young rats. Because recent
studies have described a decline in -cell replication with
age (35–37), it remains to be known whether gastrin
would increase -cell proliferation in old pancreatecto-
mized rats.
A potential additional factor contributing to increased
-cell mass is -cell hypertrophy. The study of the indi-
vidual -cell size showed that although 95%-Px induced
-cell hypertrophy, gastrin did not further increase it. The
result is in agreement with the lack of effect of gastrin
infusion on -cell size in duct-ligated rats (11).
Gastrin treatment reduced -cell apoptosis in 95%-Px
rats. The increased -cell apoptosis in 95%-Px rats treated
with vehicle was probably driven by chronic exposure to
hyperglycemia (23, 38). -Cell apoptosis was normal in
the subgroup of gastrin-treated rats that developed hyper-
glycemia, indicating that the effect of gastrin cannot be
attributed to the reduced hyperglycemia. The antiapop-
totic properties of gastrin have been shown in other cell
types such as gastrointestinal and AR42J cells (39, 40), but
we are unaware of previous data showing an antiapoptotic
action of gastrin in pancreatic -cells. In acinar cells, the
antiapoptotic action of gastrin is mediated by the phos-
phorylation of insulin receptor substrate-1, stimulation of
phosphoinositide 3-kinase, AKT, ERK, and MAPK (40).
The amidated peptides of the gastrin-cholecystokinin
(CCK) family exert their actions mainly via two G protein-
coupled receptors, CCK-A and CCK-B receptors. The
CCK-A receptor (also known as CCK-1 receptor) has an
affinity for CCK that is 100- to 500-fold greater than for
gastrin, and the CCK-B receptor (also known as CCK-2
receptor) has equivalent high affinities for both hormones
(41). In the rat, CCK-A receptors are expressed in the
normal exocrine pancreas, but CCK-B receptors are not
(16, 42–45). There is general agreement that CCK-B re-
ceptor is not expressed in adult -cells (46–48), and the
expression in - and -cells is controversial, with some
studies reporting its presence in rat and human -cells
(46), but not in  cells (48), and other studies showing
colocalization with somatostatin but not with glucagons
positive cells (47, 49). In this study, we did not detect the
expression of cckbr gene in the pancreas or in islets of SV
animals. In pancreatectomized rats, gene expression of
cckbr remained negative in islets isolated from the pan-
creatic remnant but was found in the pancreatic remnant.
The expression of the CCK-B receptor has been reported
in other experimental models of pancreatic damage, such
as partial duct ligation (45) and azaserine-induced pan-
FIG. 5. Ductal and acinar cell replication. Micrographs show BrdU
(green) and PanCK (red) double stained sections of pancreatic
remnants from vehicle-treated 95%-Px rats (PxV) (A) and gastrin-
treated 95%-Px rats (PxG,) (B), and BrdU (green) and amylase (red)
double stained sections of pancreatic remnants from PxV rats (D) and
PxG rats (E). Arrows show ductal (A and B) or acinar (C and D) cells
with immunoreactivity for BrdU in their nuclei.Quantification of ductal
cell proliferation (E) and of acinar cell proliferation (F). (PxV, n  7;
PxG, n  8). Values are means  SE. ANOVA: P  0.05; *, P  0.05
vs. all other groups for Tukey’s test.
TABLE 1. Gene expression of ccka and cckb receptors
in pancreas and isolated islets
Pancreas Islets
SV PxV SV PxV
cckar 6.59  1.67 5.65  0.59 6.53  0.15 6.17  0.45
cckbr ND 15.28  0.69 ND ND
Real-time quantitative PCR from sham pancreas (SV) (n  5),
pancreatic remnants of 95%-Px rats (PxV) (n  5), islets isolated
from SV animals (n  5), and islets isolated from pancreatic
remnants of PxV animals (n  5) was performed to identify cckar
and cckbr gene expression. Values are means  SE of Ct (target gene
Ct -endogenous control Ct). ND, Nondetectable.
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creatic carcinoma in rats (50). Although the expression of
CCK-B in newly formed extraislet -cells cannot be ex-
cluded, the results suggest that in partially pancreatecto-
mized rats, gastrin could enhance islet neogenesis acting
on the newly expressed CCK-B receptor in the exocrine
pancreas.
We detected the expression of cckar gene in pancreas as
well as in isolated islets from both sham and 95%-Px rats.
The expression in islets is in agreement with the previously
reported colocalization of insulin and CCK-A receptor
(47). The involvement of CCK-A receptor in pancreatic
growth has been previously suggested (51). Thus, al-
though gastrin is a poor activator of CCK-A receptor at
physiological concentrations (41), the dose of gastrin used
inour studymayhaveallowed the interactionwithCCK-A
receptor, providing a mechanistic basis for the effects of
gastrin on -cell replication and apoptosis.
In summary, we have found that gastrin administration
to 95%-Px rats enhanced -cell neogenesis, increased
-cell replication, and reduced -cell apoptosis. Gastrin
action on -cell regeneration and survival increased -cell
mass and improved glucose tolerance, supporting a po-
tential role of gastrin in the treatment of diabetes.
Acknowledgments
We thank the Biology Unit of the Scientific-Technical Services
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47. Morisset J, Julien S, Lainé J 2003 Localization of cholecystokinin
receptor subtypes in the endocine pancreas. J Histochem Cytochem
51:1501–1513
48. Brand SJ, Tagerud S, Lambert P, Magil SG, Tatarkiewicz K, Doiron
K, Yan Y 2002 Pharmacological treatment of chronic diabetes by
stimulating pancreatic -cell regeneration with systemic co-admin-
istration of EGF and gastrin. Pharmacol Toxicol 91:414–420
49. Morisset J, Wong H, Walsh JH, Lainé J, Bourassa J 2000 Pancreatic
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